15 Apr 05
The government's Health Select Committee has published a stinging attack on the UK pharmaceutical industry. In a report spanning 126 pages and consisting of 48 conclusions and recommendations, the committee has lambasted the way in which the UK pharmaceutical industry conducts its business and the motives by which it is driven. Datamonitor's Duncan Emerton looks at the details...
08 Apr 05
The death toll from the Marburg virus has now risen to over 150 in Angola making it the most serious such outbreak recorded. Although the Ebola-like virus has no vaccine or curative treatment and can be rapidly fatal, news of the outbreak should serve to focus attention back on the sometimes-neglected area of tropical disease management.
24 Mar 05
Despite almost 20 million global sufferers and comorbidities ranging from visible signs of infection to arthritis, there is no cure for psoriasis and public awareness of the disease remains low with up to 45% of sufferers undiagnosed. However, new biologic treatments and marketing campaigns are helping to bring psoriasis more into the public eye, to the benefit of all available products.
22 Mar 05
DOCS International in partnership with the Institute of Clinical Research (ICR) announce the launch of the CRAcademy.
This exciting new intiative aims to provide relevant practical experience for Life Science graduates and others wanting to embark on a career in the Pharmaceutical Industry.
Beginning on 1 April 2005, CRAcademy will organise core traineeships for starter clinical research professionals with Pharmaceutical Industry sponsors in key European countries.
16 Mar 05
Depression is the most common mental disorder worldwide affecting around 120 million people globally. The depression market is the largest segment of the CNS market with global sales of US$15.5 billion in 2003 although this figure is dropping as generic equivalents of past blockbusters are launched. Although the depression market has matured, key areas of unmet clinical need will have to be addressed in order to drive further growth of the market. These include improvements in the safety/tolerab
16 Mar 05
According to the WHO, 350-400 million individuals are chronically infected with the hepatitis B virus (HBV). Chronic infection with hepatitis viruses causes cirrhosis and hepatocellular carcinoma, both devastating diseases with few treatments and the demand for effective treatments for hepatitis infection is therefore high. Lamivudine dominates first-line therapy for HBV (see our feature on hepatitis B & C). Gilead's Adefovir prodrug (Hepsera) represent a second line option although nephrotoxici
16 Mar 05
Beta blockers reduce heart rate and myocardial contractility thereby reducing myocardial work load. Diastolic perfusion time is also lengthened by beta blockers supporting the use of this drug class as acute and chronic treatment following myocardial infarction. Studies have demonstrated that beta blockers can reduce total mortality, nonfatal myocardial infarction and sudden death in patients who have already suffered a myocardial infarction by 20-30%. Despite the potential benefit of beta block
16 Mar 05
Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
11 Mar 05
Biogen Idec and Elan have announced the voluntary suspension from sale and withdrawal from clinical trials of Tysabri, the companies' novel therapy for the treatment of relapse remitting multiple sclerosis (RRMS). This move has already slashed share prices of both companies. Even if Tysabri is relaunched with some form of black-box warning, doubts will surely linger over its long-term safety.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.